Last reviewed · How we verify
Exemestane and GnRH analogue
Exemestane suppresses estrogen production while a GnRH analogue suppresses ovarian function, providing dual hormonal blockade in premenopausal women with hormone receptor-positive breast cancer.
Exemestane suppresses estrogen production while a GnRH analogue suppresses ovarian function, providing dual hormonal blockade in premenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer in premenopausal women (adjuvant or metastatic setting).
At a glance
| Generic name | Exemestane and GnRH analogue |
|---|---|
| Also known as | AROMASIN, TRENATONE, ZOLADEX. |
| Sponsor | GBG Forschungs GmbH |
| Drug class | Aromatase inhibitor + GnRH agonist combination |
| Target | Aromatase enzyme; GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Exemestane is an aromatase inhibitor that blocks the conversion of androgens to estrogen in peripheral tissues. The GnRH analogue induces ovarian suppression by downregulating the hypothalamic-pituitary-gonadal axis, reducing circulating estrogen levels. Together, they provide complementary endocrine therapy by eliminating estrogen from multiple sources.
Approved indications
- Hormone receptor-positive breast cancer in premenopausal women (adjuvant or metastatic setting)
Common side effects
- Hot flashes
- Vaginal dryness
- Arthralgia
- Fatigue
- Headache
- Bone loss/osteoporosis
Key clinical trials
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (PHASE2)
- Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (PHASE3)
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (PHASE3)
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (PHASE2)
- Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 (NA)
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (PHASE3)
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) (PHASE3)
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exemestane and GnRH analogue CI brief — competitive landscape report
- Exemestane and GnRH analogue updates RSS · CI watch RSS
- GBG Forschungs GmbH portfolio CI